Anne Li 6/4/17
Every year, around 6,300 women in the UK are told they have a condition called ductal carcinoma in situ (DCIS). In the US this figure sits at over 50,000 women, while in the Netherlands 2,500 women are given this diagnosis. These women are often told the condition is a potential precursor to breast cancer. And some are even told they have stage 0 breast cancer. This information comes in spite of doctors knowing that not all women with DCIS will go on to develop cancer. What they don’t know, however, is how to tell the difference between cases that will develop into breast cancer and those that won’t. Dr Jelle Wesseling, senior group leader and consultant breast pathologist at the Netherlands Cancer Institute, and his team of 8 international scientists want to change this. Through their Grand Challenge project – which is jointly funded by Cancer Research UK and the Dutch Cancer Society – they want to help doctors give women with DCIS a definitive answer on their individual risk of developing breast cancer. So they know, once and for all, if treatment is necessary.
See original article at: http://scienceblog.cancerresearchuk.org/2017/05/24/preventing-unnecessary-breast-cancer-treatment/